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Obesity is a global health problem even among pregnant 
women. Obesity alters quality of labor, such as preterm la-
bor, prolonged labor, and higher oxytocin requirements 
in pregnant women. The most important factors to play 
a role in the altered gestational period and serve as drug 
targets to treat the consequences are female sexual hor-
mones, calcium channels, adrenergic system, oxytocin, 
and prostaglandins. However, we have limited information 
about the impact of obesity on the pregnant uterine con-
tractility and gestation time. Adipose tissue, which is the 
largest endocrine and paracrine organ, especially in obes-
ity, is responsible for the production of adipokines and vari-
ous cytokines and chemokines, and there are no reliable 
data available describing the relation between body mass 
index, glucose intolerance, and adipokines during preg-
nancy. Recent data suggest that the dysregulation of lep-
tin, adiponectin, and kisspeptin during pregnancy contrib-
utes to gestational diabetes mellitus and pre-eclampsia. A 
preclinical method for obese pregnancy should be devel-
oped to clarify the action of adipokines and assess their im-
pact in obesity. The deeper understanding of the adipok-
ines-induced processes in obese pregnancy may be a step 
closer to the prevention and therapy of preterm delivery 
or prolonged pregnancy. Gestational weight gain is one of 
the factors that could influence the prenatal development, 
birth weight, and adiposity of newborn.
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Obesity is a global health problem among pregnant wom-
en and an increasing problem in medical practice (1,2). The 
most negative consequence of obesity is the development 
of chronic low-grade metabolic inflammation, which can 
lead to other pathologic conditions (3). Obesity increases 
the risks of infertility and complications of delivery. In addi-
tion, it is not only associated with maternal morbidity, but 
also causes deleterious health consequences in the off-
spring (4-6). Obesity may alter the pregnant uterine con-
tractility and hence make the gestation period shorter or 
longer (7) (Table 1).
Preterm delivery (PD) is childbirth before 37 weeks but af-
ter 22 weeks of gestation (8,9). Approximately 15 million 
babies are preterm worldwide, the rates varying across 
countries (10). The rate of singleton preterm births seems 
to decrease slightly and remains below 6% in many Euro-
pean countries (11). However, in Austria, Belgium, Cyprus, 
Hungary, Germany, or Romania, the preterm birth rate is 
still close to or slightly beyond 10% (12).
The previous RECOOP HST Association study identified 
body mass index as one of the most significant factors 
associated with preterm births in Central and Eastern Eu-
rope (13).
Postterm pregnancy (PP), also called late-term and post-
term pregnancy, is a gestational period longer than 42 
completed weeks from the last menstrual period. The fre-
quency of PPs is highly variable, between 0.5% and 10%, 
and shows great differences among the countries. Paternal 
genetics, maternal height, obesity, and male fetal gender 
are among the factors that may have impact on PP (14). 
Although the PP incidence shows an increasing tendency, 
this type of disorder is still depreciated (15).
The exact process of PD is not clear. Decidual hemor-
rhage, cervical incompetence, uterine distortion, cervical 
and maternal inflammation, hormonal changes, utero-
placental insufficiency, preeclampsia, multiple gesta-
tion, maternal periodontal disease, and fetal disorders are 
among the factors that may lead to PD. Additional factors 
are overweight or underweight before or during preg-
nancy, hypertension, gestational diabetes, blood clotting 
disorders, in vitro fertilization, extreme maternal age (less 
than 17 or more than 35 years old), nonwhite race, and 
poverty (13,16).
The risks factors of PP are not clarified. Recently, the obesity 
is the only one risk factor of PD that is supposed to be pre-
ventable (17). The prevention and treatment of PP is also a 
challenge in obstetrics because it has many adverse fetal 
outcomes with either reduced or normal uteroplacental 
functions (18). German Birth Cohort Studies in newborns 
and mothers observed statistically significant associations 
between gestational weight gain (GWG) starting in the 
second trimester and newborn cord blood and post-deliv-
ery maternal serum leptin (19).
PHYSIOLOGICAL FACTORS AND THERAPEUTIC TARGETS 
OF PREGNANT UTERINE CONTRACTION
Female sexual hormones
The majority of the mechanisms that lead to delivery are 
under the control of estrogen and progesterone. Proges-
terone maintains pregnancy by reducing the resting tone 
of the pregnant myometrium. The estrogen-to-proges-
terone ratio determines the contractility of the pregnant 
myometrium. Estrogen enhances, while progesterone re-
duces the ability to contract (20). It was proved that the 
high plasma level of progesterone restores the function 
of β
2-adrenergic receptors at the end of pregnancy (21). 
On the other hand, progesterone has anti-inflammatory 
effect that may have high physiological and therapeutic 
importance in the inflammatory approach to PD (22). The 
sexual hormones influence the expressions of aquaporin 
5 proteins and may be potential prognostic factors in the 
presence of symptoms of threatened premature labor 
(23). The benefit of the preventive administration of 17-
alpha-hydroxyprogesterone caproate-(17-OHPC) in high 
risk PD was proved by several randomized controlled tri-
als; however, the evidence for better neonatal outcomes 
are not absolutely convincing (24). Pharmacogenomic 
studies proved that women with a special single nucle-
otide polymorphism in the progesterone receptor gene 
are at increased risk of PD during 17-OHPC therapy (25). 
The disturbance of the nuclear co-regulatory factor of 
the progesterone receptor and the subsequent low 
sensitivity of the receptors was proved in the uterine 
samples from PP (26).
TAbLE 1. Weeks of preterm, term, and postterm birth (7)
Classification of birth Gestational period (weeks)
Preterm 22-36
Late preterm 34-36
Term 37-41
Early term 37-38
Full term 39-41
Postterm 42 or greater
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Calcium channels
Voltage-dependent L-type calcium channels are crucial 
in the control of pregnant myometrial contractions. Every 
alteration in the myometrial contractility has an impact 
on the function of calcium channels and calcium influx 
into the myometrial cells. Sexual hormones can alter the 
isoforms of voltage-dependent L-type calcium channels, 
which may influence contractility and pharmacological 
reactivity (27). Calcium channel blockers inhibit calcium 
re-uptake via these channels and induce smooth muscle 
relaxation. Nifedipine is one of the most frequently used 
calcium channel blockers for preterm birth with a better 
side effect profile as compared with β2-adrenergic ago-
nists (28,29).
Adrenergic system
Alpha-adrenergic receptors are responsible for uterine 
contraction, while β2-adrenergic receptors meditate relax-
ation in the pregnant myometrium. Different types of α1- 
and α2-adrenergic receptor blockers have been investi-
gated as potential tocolytics, but none of them have been 
tried in the clinical practice (30-33). The special adrenergic 
denervation of the pregnant myometrium also contributes 
to the changes in contractility (34). β2-adrenergic agonists 
relax the smooth muscle by elevating the intracellular level 
of cyclic AMP, leading to the phosphorylation of the Ca2+ 
channels. A-kinase anchoring proteins (AKAPs) – protein ki-
nase A (PKA) disruptors – enhance the relaxing effect of β2-
adrenergic agonists (35). The combination of β2-adrenergic 
agonists with Ca2+ channel blockers (36) and phosphodi-
esterase inhibitors (37) were also investigated in preclini-
cal conditions and beneficial co-actions were found. The 
effectiveness of the therapy with beta-mimetics influences 
the genotype of the β2-receptor. The first study that inves-
tigated the pharmacogenetics of β2-adrenergic receptor 
agonist therapy in the preterm labor found that Arg16 ho-
mozygosity improved the efficacy of β2-adrenergic recep-
tor agonist-induced tocolysis (38).
Oxytocin
Oxytocin and oxytocin sensitivity of the pregnant myome-
trium are equally important in the initiation of both term 
and non-term deliveries (39). The inhibition of the oxytocin 
receptor reduces the calcium influx and inhibits the preg-
nant myometrial contractions (40). Oxytocin antagonists, 
like atosiban, act both at oxytocin and vasopressin 1A 
receptors (24). The induction of labor always requires 
external oxytocin in case of weak myometrial contractions. 
Oxytocin is routinely used labor induction at 41 weeks and 
later in case of ripe cervix. In prolonged labor, the admin-
istration of oxytocin has importance in reducing the need 
for cesarean section (41).
Prostaglandins
Cyclooxygenases (COXs) produce prostaglandins that in-
duce myometrial contractility and cervical ripening and 
are crucial for the initiation and completion of labor. Pros-
taglandins E1 and E2 reduce the dose of oxytocin for labor 
induction, although prostaglandin E2 alone did not show 
a significant increase in pregnant myometrial activity (42). 
For this reason, prostaglandin E1 analogue, misoprostol, 
is used for labor induction (43). When cervical conditions 
are not optimal, the administration of prostaglandin E2 is 
recommended to decrease the oxytocin dose (14). COXs 
inhibitors, such as indomethacin, can be used for tocoly-
sis, although several fetal side effects should be taken into 
consideration; therefore, their prolonged use is not recom-
mended (44).
THE ImPACTS OF mATERNAL ObESITY ON PREGNANCY
In contrast to pregnant women of normal weight, insulin 
resistance is higher in obese pregnant women. During the 
last trimester, the levels of maternal circulating lipid, trig-
lycerides, low- and high-density lipoproteins, and choles-
terol are significantly elevated. Maternal circulating amino 
acid concentrations are also modified due to the higher 
protein synthesis for fetal development and placental 
growth. According to these metabolic changes, lipogen-
esis is dominant in early gestation and lipolysis in late ges-
tation in women with normal body weight. On the other 
hand, the gestational weight gain is only accompanied by 
lipolysis, suggesting the exposure of fetus to increased free 
fatty acids during fetal development (45-47).
Gestational weight gain can lead to the higher incidence of 
spontaneous miscarriage and congenital abnormalities, such 
as neural tube defects or congenital heart failure (47). In later 
gestation, hypertension, preeclampsia, and gestational dia-
betes mellitus are clinically observed (48). However, several 
studies demonstrated that gestational weight gain even can 
lead to PP (49,50). The subsequent macrosomia is associated 
with higher incidence of labor induction and cesarean sec-
tion. However, small for gestational age was also more com-
mon in obese pregnancies (5). The effect of maternal obe-
sity may also seem contradictory considering the placental 
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weight. It was found that obesity increases placental weight 
and hypertrophy and this is positively correlated with birth 
weight (50,51). Other animal studies, however, showed that 
gestational high-fat diet reduces prenatal development and 
alters the placental structure (47). Gestational weight gain 
is also accompanied by a higher incidence of deep venous 
thrombophlebitis, hemorrhage after labor, breast-feeding 
difficulty, postpartum depression, and infections. However, 
infection is very rare in gestational obesity (5,49). The long-
term childhood implications include obesity, type 2 diabe-
tes mellitus, respiratory tract infections, chronic lung disease, 
bronchial asthma, and chronic obstructive pulmonary dis-
ease (52). There are many consequences of maternal obesity 
during pregnancy (Table 2).
mETAbOLIC REGULATION OF HUmAN mYOmETRIAL 
FUNCTION DURING PREGNANCY
Adipose tissue becomes a very significant endocrine 
and paracrine organ in obesity. It is responsible for the 
production of adipokines and various cytokines and 
chemokines. Adipokines play an important role in hemo-
stasis, lipid degradation, blood pressure control, athero-
sclerosis, insulin sensitivity, and angiogenesis. In addition, 
some adipokines are responsible for the immune and in-
flammation responses (53,54). The potential modulation 
of contractility by cytokines and inflammatory process-
es plays a significant role in the changes in pregnancy 
and gestational age (55). The expanding adipose tissue 
increases the chronic low-grade inflammation cytokines 
productions via immune cells. This process induces in 
metabolic complications (56). The adipose tissue func-
tions are controlled via the brain, since many neuropep-
tides and neurotrophic factors and their receptors are ex-
pressed in both adipose tissue and the central nervous 
system (53). Since adipokines influence the central and 
peripheral hypothalamic-pituitary-gonadal axis, adipose 
tissue is involved in the onset of puberty, the regulation of 
sexual behavior and fertility, their adaptation to the avail-
ability of energy, and the size of fat (3). Leptin, resistin, tu-
mor necrosis factor-alpha, omentin-1, chemerin, ghrelin, 
visfatin, interleukin-6, kisspeptin, and adiponectin belong 
to the adipokines (57). Recent data suggest that the dys-
regulation of leptin, adiponectin, and kisspeptin during 
pregnancy contributes to diabetes mellitus and pre-ec-
lampsia (54). In addition, obesity was demonstrated to 
be accompanied by the decreased level of adiponectin 
and the increased expression of leptin and kisspeptin (58); 
therefore, there is a growing interest in these adipokines 
concerning obesity and pregnancy.
Leptin
Leptin, a 16 kDa protein, plays an important role in the 
regulation of food intake and energy consumption. It re-
duces appetite by stimulating the hypothalamic leptin 
receptor (Ob-Rb) (58); therefore, dysfunction of the hy-
pothalamus or leptin signaling deficiencies may contrib-
ute to the development of increased body weight. Leptin 
was also demonstrated to influence reproductive func-
tion (59). The expression of leptin and Ob-Rb mRNAs and 
proteins was demonstrated in human endometrium and 
placental trophoblast (60), suggesting the role of leptin in 
the implantation process. It was also demonstrated that 
leptin stimulates human trophoblast invasion due to its 
effect on matrix metalloproteinase (MMP)-2 and MMP-9, 
which play an important role in implantation (61). The 
serum concentration of leptin is significantly increased 
during pregnancy and decreased after birth, revealing an 
important role during gestation. It also takes part in pla-
cental nutrient transfer (62). Two independent German 
cohort studies provided evidence on the robust asso-
ciation among GWG, fetal-maternal leptin, and fetal de-
velopment, along with the long-term consequences of 
hypo- and hyper-leptinemia during pregnancy (19). Lep-
tin was demonstrated to have relaxing effect on isolat-
ed human and rat myometria (62,63). The dysregulation 
of leptin also can lead to infertility. Leptin deficient mice 
were described to have high rates of insulin resistance 
and infertility (58).
TAbLE 2. Complications of maternal obesity*
maternal complications Fetal outcomes Childhood outcomes
PD, PP stillbirth obesity
Dystocia fetal and neonatal death hypertension
Cesarean section macrosomia type 2 diabetes mellitus
Gestational diabetes mellitus fetal growth restriction respiratory tract infection
Hypertension congenital abnormalities bronchial asthma
Eclampsia COPD
*Abbreviations: PD – preterm delivery; PP – prolonged pregnancy; COPD – chronic obstructive pulmonary disease.
RECOOP for Common Mechanisms of Diseases 100 Croat Med J. 2017;58:96-104
www.cmj.hr
Adiponectin
Adiponectin plays an important role in insulin sensitivity 
and inflammation. It circulates in the blood in high con-
centrations, as the most abundant adipokine in the circu-
lation. It has an effect on the liver, the skeletal muscle and 
the vascular system, improves hepatic insulin sensitivity 
and decreases vascular inflammation (64). Adiponectin 
acts on different adiponectin receptors. AdipoR1 is local-
ized in the skeletal muscle and stimulates AMPK and leads 
to lipid oxidation. AdipoR2 can be found in the liver and 
increasing susceptibility for insulin. The third receptor, t-
cadherin (or adiponectin-binding protein) can be found 
in the endothelium and the smooth muscle (58,64,65). 
Contrary to leptin, the serum level of adiponectin is in-
versely correlated with obesity, hypertension, serum lipids 
and coronary artery disease (66). Decreased adiponectin 
level is responsible for the development of type 2 dia-
betes mellitus. The adiponectin level decreases progres-
sively during normal pregnancies, probably in response 
to reduced insulin sensitivity, and a higher degree of de-
crease can be detected in pregnant women with obesity 
or gestational diabetes mellitus (67). Although the signal-
ing pathway of adiponectin (AMPK) has been identified 
as a mechanism important to the myometrium, no infor-
mation is available about the adiponectin effect on uter-
ine contractility.
Kisspeptin
The hypothalamic hormone kisspeptin was first discov-
ered as a metastasis suppressor peptide. It was shown lat-
er that it plays an important role in sexual maturation and 
pubertal development. It binds to the kisspeptin receptor 
(KISS1R). The deficiency of kisspeptin can lead to idiopath-
ic hypogonadotropic hypogonadism with low level of 
sexual steroids and gonadotropin hormones, as kisspeptin 
modifies the secretion of GnRH and increases the level of 
LH and FSH directly (68-70). It was also demonstrated that 
there are more kisspeptin neurons in the female than male 
rodent hypothalamus. Kisspeptin is essential in placental 
and fetal developments. The level of kisspeptin is elevated 
during gestation. In addition, high placental expression of 
KISS1R and kisspeptin has been found in the first trimester 
(68). Low kisspeptin levels in early pregnancy were found 
to be accompanied by small gestational weight and re-
current pregnancy loss (71). Obesity alters the expression 
of KISS1R and kisspeptin regulates glucose homeostasis 
and can influence the body weight (69,72). Kisspeptin 
as a neuropeptide is also produced by adipose tis-
sue (73). Mice models of obesity and type 2 diabetes mel-
litus revealed increased hepatic kisspeptin expression and 
kisspeptin plasma levels. Human liver samples from type 
2 diabetes patients showed increased kisspeptin produc-
tions. A growing number of experiments demonstrate 
that leptin action on GnRH neurons is mediated by kiss-
peptin. GnRH neurons express the KISSR1, while Ob-Rb is 
present in kisspeptin neurons in the hypothalamus (3). Ac-
cording to this data, obesity can lead to the overexpres-
sion of these adipokines, which can lead to pathophysi-
ological changes.
UTERINE CONTRACTILITY IN ObESE WOmEN
According to our recent knowledge, obesity can lead to 
both premature birth and increased incidence of cesarean 
section, while weight gain mainly leads to poor myome-
trial contractility (74). Although there are several studies 
focusing on the correlation between obesity and the in-
creased prevalence of cesarean section, the exact underly-
ing mechanisms and pathogenesis of the poor myometrial 
contractility are still questioned.
Increased body weight is positively correlated with in-
creased blood cholesterol level and responsible for 
changes in myometrial contractility (74,75). Cholesterol is 
an essential component in the cell membranes. Several 
components, which are vital in the regulation of smooth 
muscle signaling pathway, are localized in cholesterol-rich 
parts of the cell membrane, such as caveolae (76). In ani-
mal model, a high-fat high-cholesterol diet decreased the 
expressions of connexin-43 and caveolin-1 (myometrial 
contraction-associated proteins), but it increased the ex-
pression of COX-2, which can lead the poor myometrial 
contractility during obesity (77,78). The high-fat high-cho-
lesterol diet was also found to increase the expression of 
the oxytocin receptor (79), but the existing data are con-
tradictory about the influence of obesity on this receptor 
(80). The high-fat high-cholesterol diet also resulted in el-
evated plasma progesterone level at term, which may also 
give an evidence for the poor contractility during obesity 
(79). Decreased cervical ripening was also observed dur-
ing obesity (81,82). Increased leptin in obesity can induce 
adipose and placental PGE
2 release contributing to in-
flammatory processes. It also disrupts collagen degrada-
tion and apoptosis. In addition, it promotes cervical col-
lagen synthesis in late gestation, which can also result in 
delayed labor (50). Leptin also inhibits spontaneous and 
agonist induced uterine contractions on isolated human 
and rat myometrium (62,63).
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CONCLUSIONS
Gestational weight gain is an important factor during early 
fetal development and may influence long-term health of 
newborns. There is an emerging need to clarify the impacts 
of obesity and adipose tissue-produced adipokines (leptin, 
adiponectin, kisspeptin) in pregnancy. A preclinical meth-
od for obese pregnancy should be worked out to clarify 
the action of adipokines and assess their impact in obesity. 
Meanwhile, a clinical investigation should be launched in 
parallel to reveal the character and the mechanisms of the 
obesity-induced alteration in gestation length and myo-
metrial contractility. The deeper understanding of the adi-
pokines-induced processes in obese pregnancy may be a 
step closer to the prevention and therapy of preterm deliv-
ery or postterm pregnancy.
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